The BASKET study program: Continued evaluation of the efficacy and safety of drug-eluting stents

Interventional Cardiology

Volumn 3, Issue 4, 2011, Pages 461-466

  Kissel, Christine K ^a   Kaiser, Christoph ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

bare metal stents; coronary artery disease; drug eluting stents; interventional cardiology

Indexed keywords

CYPHER; EVEROLIMUS; RAPAMYCIN; UNCLASSIFIED DRUG;

BARE METAL STENT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVIEW; STENT THROMBOSIS;

EID: 80052451916     PISSN: 17555302     EISSN: 17555310     Source Type: Journal    
DOI: 10.2217/ica.11.44     Document Type: Review

References (27)

1. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346, 1773-1780 (2002). (Pubitemid 34586912)
2. Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med. 356, 998-1008 (2007). (Pubitemid 46376800)
3. Kaiser C, Brunner-La Rocca HP, Buser PT et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET).Lancet 366, 921-929 (2005). (Pubitemid 41265666)
4. Brunner-La Rocca HP, Kaiser C, Bernheim A et al. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitats Trial (BASKET): an 18-month analysis. Lancet 370, 1552-1559 (2007). (Pubitemid 350018894)
5. Brunner-La Rocca HP, Kaiser C, Pfisterer M; BASKET Investigators. Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET).Eur. Heart J. 28, 719-725 (2007). (Pubitemid 46439229)
6. Pfisterer M, Brunner-La Rocca HP, Buser PT et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 48, 2584-2591 (2006). (Pubitemid 44881238)
7. Steinberg DH, Mishra S, Javaid A et al. Comparison of effectiveness of bare metal stents versus drug-eluting stents in large >or =35 mm) coronary arteries. Am. J. Cardiol. 99, 599-602 (2007).
8. Ellis SG, Colombo A, Grube E et al. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J. Am. Coll. Cardiol. 49, 1043-1051 (2007). (Pubitemid 46357591)
9. Weisz G, Leon MB, Holmes DR Jr et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J. Am. Coll. Cardiol. 47, 1350-5 (2006).
10. Pfisterer M, Brunner-La Rocca HP, Rickenbacher P et al. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. Eur. Heart J. 30, 16-24 (2009).
11. Gordon PC, Applegate RJ, Hermiller JB et al. Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 40 mm registry. Catheter Cardiovasc. Interv. 75, 179-186 (2010).
12. Akiyama T, Moussa I, Reimers B et al. Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels. J. Am. Coll. Cardiol. 32, 1610-1618 (1998). (Pubitemid 28545198)
13. Kaiser C, Galatius S, Erne P et al. Drug-eluting versus bare-metal stents in large coronary arteries. N. Engl. J. Med. 363, 2310-2319 (2010).
14. Kirtane AJ, Ellis SG, Dawkins KD et al. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J. Am. Coll. Cardiol. 51, 708-715 (2008). (Pubitemid 351227416)
15. Chan C, Zambahari R, Kaul U et al. A randomized comparison of sirolimus-eluting versus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: the DECODE study. Catheter Cardiovasc. Interv. 72, 591-600 (2008).
16. Baumgart D, Klauss V, Baer F et al. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. J. Am. Coll. Cardiol. 50, 1627-1634 (2007). (Pubitemid 47562680)
17. Maresta A, Varani E, Balducelli M et al. Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study).Am. J. Cardiol. 101, 1560-1566 (2008).
18. Stettler C, Allemann S, Wandel S et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 337, a1331 (2008).
19. Garg P, Charytan DM, Novack L et al. Impact of moderate renal insufficiency on restenosis and adverse clinical events after sirolimus-eluting and bare metal stent implantation (from the SIRIUS trials).Am. J. Cardiol. 106, 1436-1442 (2010).
20. Serruys PW, Onuma Y, Garg S et al. 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J. Am. Coll. Cardiol. 55, 1093-1101 (2010).
21. Nakagawa Y, Kimura T, Morimoto T et al. Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher Registry).Am. J. Cardiol. 106, 329-336 (2010).
22. Cosgrave J, Corbett SJ, Melzi G et al. Late restenosis following sirolimus-eluting stent implantation. Am. J. Cardiol. 100, 41-44 (2007). (Pubitemid 46961896)
23. Hong MK, Mintz GS, Lee CW et al. Late target lesion revascularization after implantation of sirolimus-eluting stent. Catheter Cardiovasc. Interv. 71, 299-303 (2008). (Pubitemid 351428145)
24. Rodriguez AE, Maree AO, Mieres J et al. Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry. Eur. Heart J. 28, 2118-2125 (2007). (Pubitemid 47517450)
25. Claessen BE, Beijk MA, Legrand V et al. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. Circ. Cardiovasc. Interv. 2, 339-347 (2009).
26. Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372, 1163-1173 (2008).
27. Nakazawa G, Granada JF, Alviar CL et al. Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc. Interv. 3, 68-75 (2010).